By Jaime Llinares Taboada

 

AstraZeneca PLC said Friday that trials to study the combination of the tremelimumab monoclonal antibody and Imfinzi demonstrated overall survival benefit for patients with liver cancer.

Ghassan Abou-Alfa, the principal investigator in the trial, said the combination of these antibodies boosts the patient's immune system against liver cancer, aiming to maximize long-term survival with minimal side effects.

This Phase 3 trial involved 1,324 patients in 16 countries and compared the tremelimumab-Imfinzi therapy against sorafenib, a standard-of-care multi-kinase inhibitor.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

October 15, 2021 02:34 ET (06:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2021 a Dic 2021 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Dic 2020 a Dic 2021 Clicca qui per i Grafici di Astrazeneca